Please assess the completion status of the following clinical trial:

Trial Title: Persistence of IPV Immunity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~We will be including Nepali infants who fulfil the following criteria:~* Born after 30 April 2016~* Healthy infant or mild illness~* Age groups within one of the following age groups: 7-12 months or \>24 months.~* Receipt of one dose of IPV at 3- 6 months of age (if age \>24months) or zero doses (if age within 7-12 months). IPV receipt must be validated through immunization card or registry book.~* Parents that consent for participation in the full length of the study.~* Parents those are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.~* Acute infection or illness at the time of enrollment that would require infant's admission to a hospital.~* Evidence of a chronic medical condition identified by a study medical officer during physical exam.~* Known allergy/sensitivity or reaction to polio vaccines.~Discontinuation Criteria~* Withdrawal of consent for participation for any reason.~* Request by parents of participant to terminate all study procedures.~* Identification of immunodeficiency disorder, bleeding disorder or another medical condition for which continued participation, in the opinion of the principal investigator, would pose a risk to the participant to continue in the study.~* Receipt of immunosuppressive medications.~* Receipt of any polio (OPV or IPV) vaccine outside of study after enrollment (as per parent's report).~* Allergic reaction to a dose of polio vaccine.~* Unable to collect or obtain blood at enrollment.~* Premature termination of the study.~* Temporary discontinuation of study activities may occur if there is a mOPV2 campaign.

- Gender: ALL
- Minimum Age: 7 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Study Arm A (Type: ACTIVE_COMPARATOR): Children {Age \> 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
- Study arm B (Type: ACTIVE_COMPARATOR): Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month

Based on this trial design, predict the completion outcome and termination type (if applicable).